ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) NonCurrent Deferred Liabilities: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:R9Z ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
6 GF Score
Price €0.37
! 5 Warning Signs
View Full Analysis

What is ImmuneOnco Biopharmaceuticals (Shanghai) NonCurrent Deferred Liabilities?

ImmuneOnco Biopharmaceuticals (Shanghai) FRA:R9Z +11.52% 6 NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:R9Z with a GF Score™ of 6/100. The stock has 5 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

ImmuneOnco Biopharmaceuticals (Shanghai)'s non-current deferred liabilities for the quarter that ended in Dec. 2025 was €0.00 Mil.

ImmuneOnco Biopharmaceuticals (Shanghai) NonCurrent Deferred Liabilities Related Terms

ImmuneOnco Biopharmaceuticals (Shanghai) NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuneOnco Biopharmaceuticals (Shanghai) NonCurrent Deferred Liabilities Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
0.00 0.00 0.00 0.00 0.00

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:R9Z
6GF Score
ImmuneOnco Biopharmaceuticals (Shanghai) Inc FRA:R9Z
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €0.00 Mil mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a NonCurrent Deferred Liabilities of €0.00 Mil as of Dec. 2025. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s NonCurrent Deferred Liabilities too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current NonCurrent Deferred Liabilities is €0.00 Mil. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s NonCurrent Deferred Liabilities compare to VRTX and REGN?
ImmuneOnco Biopharmaceuticals (Shanghai)'s NonCurrent Deferred Liabilities of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current NonCurrent Deferred Liabilities is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current NonCurrent Deferred Liabilities of €0.00 Mil. The current NonCurrent Deferred Liabilities is €0.00 Mil. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current NonCurrent Deferred Liabilities is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ImmuneOnco Biopharmaceuticals (Shanghai) Business Description

Other Exchanges 01541:Hong Kong
Address 1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score

Get the complete analysis for FRA:R9Z

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price